Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
vantictumab (OMP-18R5)
i
Other names:
OMP-18R5, OMP 18R5, OMP18R5
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Mereo Biopharma, Novartis
Drug class:
Wnt signalling pathway inhibitor
Related drugs:
‹
PRI724 (5)
WNT974 (2)
BC2059 (2)
CGX1321 (1)
NCB-0846 (1)
XAV-939 (1)
Circ0003039 (0)
E7386 (0)
KY1022 (0)
OMP-54F28 (0)
PRI724 (5)
WNT974 (2)
BC2059 (2)
CGX1321 (1)
NCB-0846 (1)
XAV-939 (1)
Circ0003039 (0)
E7386 (0)
KY1022 (0)
OMP-54F28 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
6-gene WNT pathway signature
HER2 Negative Breast Cancer
6-gene WNT pathway signature
HER2 Negative Breast Cancer
OMP-18R5
Sensitive: C3 – Early Trials
OMP-18R5
Sensitive
:
C3
OMP-18R5
Sensitive: C3 – Early Trials
OMP-18R5
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.